JNCE Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Jounce Therapeutics, Inc.

Jounce Therapeutics Announces Closing of Tender Offer

3 years ago - By: Jounce Therapeutics, Inc.

Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

3 years ago - By: Benzinga - Mentions: CRBP BLPH PRVB RPHM

Top 5 Health Care Stocks That May Crash In March

3 years ago - By: Benzinga

Jounce Therapeutics Says JTX-8064/Pimivalimab Shows Deep, Durable Responses In Pretreated Ovarian Cancer Patients

3 years ago - By: InvestorPlace - Mentions: BOXD INPX LYLT

Why Is Boxed (BOXD) Stock Down 41% Today?

3 years ago - By: InvestorPlace - Mentions: AMC

Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?

3 years ago - By: Halper Sadeh LLC

JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders

3 years ago - By: Seeking Alpha

Jounce stock jumps as Concentra agrees to buy (NASDAQ:JNCE)

3 years ago - By: Jounce Therapeutics, Inc.

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

3 years ago - By: Jounce Therapeutics, Inc.

Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer

3 years ago - By: InvestorPlace - Mentions: INPX LYLT

Why Is Inpixon (INPX) Stock Down 34% Today?

3 years ago - By: InvestorPlace - Mentions: STBX SWVL LYLT HUBC ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

3 years ago - By: Jounce Therapeutics, Inc.

Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

3 years ago - By: Kahn Swick & Foti, LLC

JOUNCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Jounce Therapeutics, Inc. - JNCE

3 years ago - By: Seeking Alpha - Mentions: RJF

Jounce Therapeutics downgraded to market perform at Raymond James (NASDAQ:JNCE)

3 years ago - By: Ademi LLP

JOUNCE THERAPEUTICS INC (JNCE) Stock News

JNCE Latest News, Press Relases and Analysis

Jounce Therapeutics Announces Closing of Tender Offer

Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

Top 5 Health Care Stocks That May Crash In March

Jounce Therapeutics Says JTX-8064/Pimivalimab Shows Deep, Durable Responses In Pretreated Ovarian Cancer Patients

Why Is Boxed (BOXD) Stock Down 41% Today?

Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?

JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders

Jounce stock jumps as Concentra agrees to buy (NASDAQ:JNCE)

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer

Why Is Inpixon (INPX) Stock Down 34% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

JOUNCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Jounce Therapeutics, Inc. - JNCE

Jounce Therapeutics downgraded to market perform at Raymond James (NASDAQ:JNCE)

Shareholder Alert: Ademi LLP investigates whether Jounce Therapeutics, Inc. has obtained a Fair Price in its transaction with RedX Pharma